Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous stem cell transplantation for AL amyloidosis
ISRCTN01207094Phase 2Completed
- Sponsor
- HOVON
- Start
- Sep 2000
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of vincristine, doxorubicin, dexamethasone, filgrastim and melphalan in light-chain amyloidosis, sponsored by HOVON. Primary endpoints: Response and Overall survival. Started Sep 2000; status: completed.
02
Drugs
vincristinedoxorubicindexamethasonefilgrastimmelphalan
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on ISRCTN01207094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN01207094.